BR112019022280A2 - tratamento de cânceres de her2 positivo - Google Patents
tratamento de cânceres de her2 positivo Download PDFInfo
- Publication number
- BR112019022280A2 BR112019022280A2 BR112019022280A BR112019022280A BR112019022280A2 BR 112019022280 A2 BR112019022280 A2 BR 112019022280A2 BR 112019022280 A BR112019022280 A BR 112019022280A BR 112019022280 A BR112019022280 A BR 112019022280A BR 112019022280 A2 BR112019022280 A2 BR 112019022280A2
- Authority
- BR
- Brazil
- Prior art keywords
- positive cancer
- her2 positive
- cancer treatment
- individual
- comprises administering
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950003463 tucatinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491872P | 2017-04-28 | 2017-04-28 | |
| PCT/US2018/029899 WO2018201016A1 (en) | 2017-04-28 | 2018-04-27 | Treatment of her2 positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019022280A2 true BR112019022280A2 (pt) | 2020-05-19 |
Family
ID=62165692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019022280A BR112019022280A2 (pt) | 2017-04-28 | 2018-04-27 | tratamento de cânceres de her2 positivo |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11207324B2 (enExample) |
| EP (1) | EP3615067A1 (enExample) |
| JP (2) | JP7328151B2 (enExample) |
| KR (1) | KR102845148B1 (enExample) |
| CN (1) | CN111032082B (enExample) |
| AU (2) | AU2018258663B2 (enExample) |
| BR (1) | BR112019022280A2 (enExample) |
| CA (1) | CA3060407A1 (enExample) |
| EA (1) | EA201992573A1 (enExample) |
| MA (1) | MA49059A (enExample) |
| SG (1) | SG11201909676WA (enExample) |
| WO (1) | WO2018201016A1 (enExample) |
| ZA (1) | ZA201907225B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7328151B2 (ja) | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Ｈｅｒ２陽性がんの処置 |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| BR112021024970A2 (pt) * | 2019-06-11 | 2022-01-25 | Univ Texas | Uso de um agonista rxr no tratamento de cânceres her2+ |
| CN114746094A (zh) * | 2019-10-21 | 2022-07-12 | 思进公司 | 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法 |
| WO2021097220A1 (en) * | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| IL298538A (en) * | 2020-05-29 | 2023-01-01 | Seagen Inc | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| AU2021315520A1 (en) * | 2020-07-29 | 2023-02-09 | Seagen Inc. | Methods of treating HER2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a VEGFR-2 antagonist |
| MX2023003406A (es) * | 2020-09-28 | 2023-03-31 | Seagen Inc | Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
| WO2024183622A1 (zh) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| WO2025132522A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| KR100953246B1 (ko) | 2003-08-14 | 2010-04-16 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| US20100063074A1 (en) | 2004-06-03 | 2010-03-11 | Berger Mark S | Cancer Treatment Method |
| DE602006009968D1 (de) | 2005-11-15 | 2009-12-03 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| JP2010540460A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
| HUE035182T2 (hu) | 2008-03-18 | 2018-05-02 | Genentech Inc | Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi |
| LT2719708T (lt) * | 2009-11-13 | 2018-02-12 | Daiichi Sankyo Europe Gmbh | Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai |
| ES2701929T3 (es) * | 2011-05-19 | 2019-02-26 | Laboratory Corp America Holdings | Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer |
| KR102061917B1 (ko) | 2011-10-14 | 2020-01-02 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
| AU2012322039C1 (en) | 2011-10-14 | 2021-04-29 | Array Biopharma Inc. | Solid dispersions of a Erb2 (HER2) inhibitor |
| SI2827900T1 (en) | 2012-03-23 | 2018-06-29 | Array Biopharma, Inc. | Amorphous solid dispersion for use in the treatment of brain cancer |
| BR112017000800A8 (pt) * | 2014-07-17 | 2023-04-25 | Biocurity Holdings Inc | Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN109952306A (zh) * | 2016-04-19 | 2019-06-28 | 加利福尼亚大学董事会 | ErbB抑制剂及其用途 |
| JP7328151B2 (ja) | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Ｈｅｒ２陽性がんの処置 |
| WO2019241599A1 (en) | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| TW202042820A (zh) | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| CN114746094A (zh) | 2019-10-21 | 2022-07-12 | 思进公司 | 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法 |
| WO2021097220A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| EP4118237A1 (en) | 2020-03-11 | 2023-01-18 | Seagen Inc. | Methods of treating her2 mutant cancers with tucatinib |
-
2018
- 2018-04-27 JP JP2019558369A patent/JP7328151B2/ja active Active
- 2018-04-27 EA EA201992573A patent/EA201992573A1/ru unknown
- 2018-04-27 US US16/607,850 patent/US11207324B2/en active Active
- 2018-04-27 MA MA049059A patent/MA49059A/fr unknown
- 2018-04-27 CN CN201880043831.3A patent/CN111032082B/zh active Active
- 2018-04-27 AU AU2018258663A patent/AU2018258663B2/en active Active
- 2018-04-27 CA CA3060407A patent/CA3060407A1/en active Pending
- 2018-04-27 EP EP18724716.8A patent/EP3615067A1/en active Pending
- 2018-04-27 SG SG11201909676W patent/SG11201909676WA/en unknown
- 2018-04-27 WO PCT/US2018/029899 patent/WO2018201016A1/en not_active Ceased
- 2018-04-27 KR KR1020197035001A patent/KR102845148B1/ko active Active
- 2018-04-27 BR BR112019022280A patent/BR112019022280A2/pt unknown
-
2019
- 2019-10-30 ZA ZA2019/07225A patent/ZA201907225B/en unknown
-
2021
- 2021-11-18 US US17/530,265 patent/US11666572B2/en active Active
-
2022
- 2022-09-28 AU AU2022241509A patent/AU2022241509B2/en active Active
-
2023
- 2023-04-26 US US18/139,653 patent/US12048698B2/en active Active
- 2023-08-03 JP JP2023126666A patent/JP2023145689A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018258663A1 (en) | 2019-11-14 |
| CN111032082A (zh) | 2020-04-17 |
| US20230390290A1 (en) | 2023-12-07 |
| US20200188401A1 (en) | 2020-06-18 |
| JP2020517696A (ja) | 2020-06-18 |
| EA201992573A1 (ru) | 2020-04-06 |
| MA49059A (fr) | 2021-03-24 |
| AU2022241509A1 (en) | 2022-10-27 |
| CA3060407A1 (en) | 2018-11-01 |
| ZA201907225B (en) | 2023-11-29 |
| JP7328151B2 (ja) | 2023-08-16 |
| US12048698B2 (en) | 2024-07-30 |
| US20220168303A1 (en) | 2022-06-02 |
| US11666572B2 (en) | 2023-06-06 |
| KR102845148B1 (ko) | 2025-08-20 |
| AU2022241509B2 (en) | 2025-02-20 |
| JP2023145689A (ja) | 2023-10-11 |
| SG11201909676WA (en) | 2019-11-28 |
| WO2018201016A1 (en) | 2018-11-01 |
| CN111032082B (zh) | 2025-01-07 |
| KR20200014298A (ko) | 2020-02-10 |
| AU2018258663B2 (en) | 2022-08-04 |
| US11207324B2 (en) | 2021-12-28 |
| EP3615067A1 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| ZA202206806B (en) | Benzooxazole derivatives as immunomodulators | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| BR112019005305A2 (pt) | compostos espirocíclicos | |
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| MX2020013120A (es) | Tratamiento terapéutico de cánceres de microsatélites inestables. | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| BR112019006329A2 (pt) | métodos de tratamento de câncer do trato biliar | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| BR112019011350A2 (pt) | terapia de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SEAGEN INC. (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |